US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kyverna Therapeutics

2.10

-0.0400-1.87%

Post-market: 2.100.00000.00%16:05 EDT

Volume:153.95K

Turnover:325.55K

Market Cap:90.76M

PE:-0.63

High:2.22

Open:2.11

Low:2.07

Close:2.14

Loading ...

Overview Company News Filings

What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock

Kyverna Therapeutics Names Naji Gehchan as Chief Medical, Development Officer

MT Newswires Live

Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief

Kyverna appoints Naji Gehchan as Chief Medical and Development Officer

Kyverna Therapeutics Appoints Naji Gehchan, Md, MBA, as Chief Medical and Development Officer

THOMSON REUTERS

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation

Simply Wall St.

Kyverna Therapeutics: Strong Buy Rating Backed by Strategic Focus and Robust Financial Health

BRIEF-Kyverna Therapeutics To Highlight Near-Term Strategic Priorities And Key Milestones At The 43Rd Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43Rd Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS

Kyverna Therapeutics Inc - Has Cash Runway Into 2027

THOMSON REUTERS

BRIEF-Unnatural Products Appoints Abbas Kazimi And Mert Aktar To Board

Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors

THOMSON REUTERS

Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors

Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles

MT Newswires Live

Kyverna Therapeutics announces senior leadership appointments

Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

THOMSON REUTERS

Press Release: Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

Kyverna shares remain ‘significantly under-valued,’ says JPMorgan

Optimistic Buy Rating for Kyverna Therapeutics Driven by Promising KYV-101 Data and Pipeline Expansion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KYTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":2.1,"timestamp":1745611200000,"preClose":2.14,"halted":0,"volume":153952,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"16:05 EDT","volume":1343,"amount":2820.3,"timestamp":1745611509952},"delay":0,"floatShares":22444852,"shares":43218873,"eps":-3.325379,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-25 16:00:00 EDT","open":2.11,"high":2.2185,"low":2.065,"amount":325550.9888,"amplitude":0.071729,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.325379,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.04,"preClose":2.14,"latestTime":"08:47 EDT","volume":3,"amount":6.12,"timestamp":1745585222805},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"16:05 EDT","volume":1343,"amount":2820.3,"timestamp":1745611509952},"volumeRatio":0.5580364909759812,"impliedVol":1.1259,"impliedVolPercentile":0.76},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":22444852,"roa":"-46.93%","roe":"-80.74%","lyrEps":-3.325379,"volumeRatio":0.5580364909759812,"shares":43218873,"dividePrice":0,"high":2.2185,"amplitude":0.071729,"preClose":2.14,"low":2.065,"week52Low":1.78,"pbRate":"0.34","psRate":"321.84","week52High":17.55,"institutionHeld":0,"latestPrice":2.1,"eps":-3.325379,"divideRate":0,"volume":153952,"delay":0,"ttmEps":-3.325379,"open":2.11,"prevYearClose":3.74,"prevWeekClose":1.86,"prevMonthClose":1.93,"prevQuarterClose":1.93,"fiveDayClose":1.86,"twentyDayClose":2.355,"sixtyDayClose":3.24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510895453","title":"What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2510895453","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510895453?lang=en_us&edition=fundamental","pubTime":"2025-02-11 01:00","pubTimestamp":1739206811,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc.  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.As such, the Zacks rating upgrade for Kyverna Therapeutics, Inc. is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.For Kyverna Therapeutics, Inc. rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.This company is expected to earn -$3.29 per share for the fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-kyverna-therapeutics-inc-kytx-170011008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2505105738","title":"Kyverna Therapeutics Names Naji Gehchan as Chief Medical, Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505105738","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505105738?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:17","pubTimestamp":1737497842,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics  said late Tuesday it appointed Naji Gehchan as chief medical and development officer.Gehchan most recently served as the head of clinical development for the imlunestrant breast cancer treatment at Eli Lilly .Shares of Kyverna Therapeutics were up 3% in after-hours trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4599","SG9999015945.SGD","LU1988902786.USD","LU0203201768.USD","LU0079474960.USD","LU0471298694.HKD","SG9999015952.SGD","LU0109391861.USD","LU0385154629.USD","BK4581","LU1548497426.USD","KYTX","LU0882574139.USD","LU2063271972.USD","LU2237443382.USD","LU1551013425.SGD","LU2265009873.SGD","LU0823416689.USD","LU2491049909.HKD","LU2211815571.USD","LU2468319806.SGD","LU1551013342.USD","LU0672654240.SGD","SG9999014906.USD","LU2491050154.USD","LU1093756325.SGD","LU2112291526.USD","LU2106854487.HKD","LU0640476718.USD","LU1623119135.USD","LU2237443978.SGD","IE00BJT1NW94.SGD","SG9999018865.SGD","LU0106261372.USD","SG9999014914.USD","LU0417517546.SGD","LU1093756168.USD","LU1720051017.SGD","LU1804176565.USD","BK4534","LU1069344957.HKD","SG9999001176.USD","LU1712237335.SGD","LLY","LU1267930730.SGD","LU0203202063.USD","LU1868836757.USD","LU0114720955.EUR","LU2237443549.SGD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2505738174","title":"Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2505738174","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505738174?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:17","pubTimestamp":1737497820,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer.The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant.As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board.Borie in the past acted as the founding CEO at Kyverna.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2505782285","title":"Kyverna appoints Naji Gehchan as Chief Medical and Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505782285","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505782285?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:10","pubTimestamp":1737493823,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) announced the appointment of Naji Gehchan, to Chief Medical and Development Officer, where he will lead the Company’s r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-appoints-naji-gehchan-as-chief-medical-and-development-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-appoints-naji-gehchan-as-chief-medical-and-development-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2505661784","title":"Kyverna Therapeutics Appoints Naji Gehchan, Md, MBA, as Chief Medical and Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505661784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505661784?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:05","pubTimestamp":1737493504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUA8GF9G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2505826707","title":"Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505826707","media":"PR Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505826707?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:05","pubTimestamp":1737493500,"startTime":"0","endTime":"0","summary":"Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth. EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr.Gehchan brings 20 years of U.S. and international experience across multiple therapeutic areas, including immunology, as both an accomplished pharmaceutical executive and a physician to this newly established role at Kyverna.\"Having worked with Naji at Lilly, I witnessed his disciplined and patient-centered approach to tackling critical business priorities and believe his unique background is a pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kyverna-therapeutics-appoints-naji-gehchan-210500323.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kyverna-therapeutics-appoints-naji-gehchan-210500323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4139","MD","KYTX"],"gpt_icon":0},{"id":"2503547648","title":"Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2503547648","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503547648?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:19","pubTimestamp":1736943586,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.So should Kyverna Therapeutics  shareholders be worried about its cash burn?For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.Since it has a market capitalisation of US$144m, Kyverna Therapeutics' US$98m in cash burn equates to about 68% of its market value. That's very high expenditure relative to the company's size, suggesting it is an extremely high risk stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-watching-kyverna-121946394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4139","USJW.SI","IE00BKPKM429.USD","NVIW.SI","NDAQ","MNQmain",".IXIC","IE00B64PRP62.GBP","TSYW.SI","LU2210149790.SGD","BK4112","KYTX","IE00B3QW5Z07.USD","QLD","USAW.SI","IE00BGHQF748.EUR","PSQ","LU2210150020.SGD","LU2095319765.USD","QID","SQQQ","BK4585","BK4588","TQQQ"],"gpt_icon":1},{"id":"2503533925","title":"Kyverna Therapeutics: Strong Buy Rating Backed by Strategic Focus and Robust Financial Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2503533925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503533925?lang=en_us&edition=fundamental","pubTime":"2025-01-14 04:37","pubTimestamp":1736800655,"startTime":"0","endTime":"0","summary":"Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report). The associated price...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kyverna-therapeutics-strong-buy-rating-backed-by-strategic-focus-and-robust-financial-health?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kyverna-therapeutics-strong-buy-rating-backed-by-strategic-focus-and-robust-financial-health?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"gpt_icon":0},{"id":"2503975302","title":"BRIEF-Kyverna Therapeutics To Highlight Near-Term Strategic Priorities And Key Milestones At The 43Rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2503975302","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503975302?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:50","pubTimestamp":1736776247,"startTime":"0","endTime":"0","summary":"BRIEF-Kyverna Therapeutics To Highlight Near-Term Strategic Priorities And Key Milestones At The 43Rd Annual J.P. Morgan Healthcare ConferenceJan 13 (Reuters) - Kyverna Therapeutics Inc KYTX.O:KYVERNA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA11YGLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2503649305","title":"Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43Rd Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2503649305","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503649305?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:30","pubTimestamp":1736771403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA11YGLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2503056473","title":"Kyverna Therapeutics Inc - Has Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2503056473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503056473?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:30","pubTimestamp":1736771403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA11YGLQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2501472740","title":"BRIEF-Unnatural Products Appoints Abbas Kazimi And Mert Aktar To Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2501472740","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501472740?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:54","pubTimestamp":1736344457,"startTime":"0","endTime":"0","summary":"BRIEF-Unnatural Products Appoints Abbas Kazimi And Mert Aktar To BoardJan 8 (Reuters) - Kyverna Therapeutics Inc KYTX.O:UNNATURAL PRODUCTS APPOINTS ABBAS KAZIMI AND MERT AKTAR TO BOARD OF DIRECTORSSource text: nGNXgswYbFurther company coverage: KYTX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA3PKLF5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2501721634","title":"Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501721634","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501721634?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA3PKLF5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2501223667","title":"Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501223667","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501223667?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"SANTA CRUZ, Calif., Jan. 08, 2025  -- Unnatural Products, Inc. , a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors.Mert Aktar is a seasoned life sciences executive with over 20 years of global experience bridging science and business in pharmaceuticals and biotechnology. He currently serves as the CEO of Receptive Bio, a privately held biotech company, and holds Board positions with Kyverna Therapeutics , ReAlta Life Sciences and UCLA Technology Development Group. Prior to joining Receptive Bio, Mr. Aktar was the Senior Vice President and Global Head of Corporate Development & Strategy at Kite Pharma. In this position, Mr. Aktar played a key role in establishing Kite's global leadership in cell therapy, architecting strategy and executing numerous deals, which strengthened Kite's R&D portfolio and drove its global expansion. Previously, Mr. Aktar ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unnatural-products-appoints-abbas-kazimi-130000071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0251131958.USD","BK4585","IE00BMG7P702.HKD","KYTX","LU2463526074.USD","LU0124384867.USD","IE00BLSP4239.USD","BK4581","LU1303367103.USD","LU1894683348.USD","LU2756315664.SGD","LU0949170772.SGD","IE00BBT3K403.USD","LU1861219969.SGD","IE00BD4GTW91.USD","IE00BMG7P819.SGD","BK4534","LU1894683264.USD","IE00BD4GTV84.USD","LU1003077747.HKD","LU0251142724.SGD","LU1978683503.SGD","LU0738911758.USD","LU1551013425.SGD","LU0820561909.HKD","LU0661504455.SGD","LU0312595415.SGD","IE00B29SXK94.USD","LU2098885051.SGD","LU2360107325.USD","LU0553294199.USD","IE00BMG7P694.USD","BK4139","LU0868494617.USD","LU0820562030.AUD","LU0048573561.USD","LU0689472784.USD","BK4588","IE00BMG7P926.USD","LU1551013342.USD","LU0545039389.USD","LU1861214812.USD","LU0354030511.USD","LU0742534661.SGD","IE00BD4GTT62.SGD","BK4532","UNP","LU0943347566.SGD","IE00BMG7P587.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2491586616","title":"Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2491586616","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491586616?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:50","pubTimestamp":1734126609,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) said late Friday it appointed Dan Maziasz and Cara Bauer as chief business officer and chief human resources officer, respectively.Maziasz was previously the chief business","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATRA","BK4139","BK4080","KYTX","KRG","SGR.SI","BK6046","BK4231"],"gpt_icon":0},{"id":"2491426583","title":"Kyverna Therapeutics announces senior leadership appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2491426583","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491426583?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:10","pubTimestamp":1734124236,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-announces-senior-leadership-appointments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-announces-senior-leadership-appointments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2491833155","title":"Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2491833155","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491833155?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:05","pubTimestamp":1734123902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUADSPW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2491583517","title":"Press Release: Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2491583517","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491583517?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:05","pubTimestamp":1734123900,"startTime":"0","endTime":"0","summary":"Key Leadership Appointments Bring New Skills and Capabilities to Organization. EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations.\"I'm pleased to welcome three industry leaders to our Kyverna team,\" said Warner Biddle, Chief Executive Officer of Kyverna. \"Dan, Cara and Tracy bring important new skills and capabilities to Kyverna as we continue to support the company's next phase of growth and work to bring a transformative change to patients living with severe autoimmune diseases.\". Ms. Rossin brings more than 20 years of strategic communications experience to Kyverna, having most recently served as the Head of Public Affa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TISI","KYTX","BK4120","AAQC"],"gpt_icon":0},{"id":"2488919338","title":"Kyverna shares remain ‘significantly under-valued,’ says JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2488919338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488919338?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:10","pubTimestamp":1733227828,"startTime":"0","endTime":"0","summary":"JPMorgan believes Kyverna Therapeutics (KYTX)’ KYV-101 stands out as a competitive treatment option for stiff person syndrome with the potential to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-shares-remain-significantly-under-valued-says-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-shares-remain-significantly-under-valued-says-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211328371.USD","LU1064131342.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0971096721.USD","LU1894683348.USD","LU0256863811.USD","LU1261432733.SGD","IE0034235303.USD","LU2023250843.SGD","LU0310799852.SGD","LU1917777945.USD","LU1668664300.SGD","IE00B775SV38.USD","LU0203347892.USD","IE00BJTD4N35.SGD","IE00BYXW3230.USD","LU0211327993.USD","LU1032466523.USD","IE0034235295.USD","IE00BLSP4239.USD","LU1974910355.USD","BK4588","IE00BHPRN162.USD","IE00BLSP4452.SGD","LU2023250504.SGD","LU0149725797.USD","LU0048584097.USD","LU1914381329.SGD","IE00B1BXHZ80.USD","LU2552382215.SGD","IE00BZ1G4Q59.USD","BK4534","IE00BKVL7J92.USD","LU2264538146.SGD","LU1244550221.USD","LU0106831901.USD","LU0211326755.USD","LU0417517546.SGD","BK4139","LU2106854487.HKD","LU2242649171.HKD","LU2552382132.HKD","IE00BDCRKT87.USD","LU0683600562.USD","SG9999002224.SGD","LU1267930490.SGD","IE0034235188.USD","LU0323591593.USD","KYTX"],"gpt_icon":0},{"id":"2485439780","title":"Optimistic Buy Rating for Kyverna Therapeutics Driven by Promising KYV-101 Data and Pipeline Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2485439780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485439780?lang=en_us&edition=fundamental","pubTime":"2024-11-21 14:15","pubTimestamp":1732169758,"startTime":"0","endTime":"0","summary":"Analyst Thomas Smith from Leerink Partners maintained a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report) and keeping the price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-kyverna-therapeutics-driven-by-promising-kyv-101-data-and-pipeline-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-kyverna-therapeutics-driven-by-promising-kyv-101-data-and-pipeline-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"KYTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2024-11-13","symbol":"KYTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.77,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1728619200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2025-04-25","current":-0.72553,"percent":0.94386,"low":-26.836094,"twenty":-10.892017,"median":-3.196968,"eighty":-1.264073,"high":-0.620373,"avg":-6.724403,"sd":7.738838,"marketCap":92488388},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-6.996941,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":531179806},{"date":"2024-06-07","current":-7.68982,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":583780403},{"date":"2024-06-14","current":-8.200961,"twenty":-25.032152,"median":-16.052332,"eighty":-8.699606,"marketCap":622584123},{"date":"2024-06-21","current":-4.560506,"twenty":-24.987544,"median":-15.898773,"eighty":-8.182787,"marketCap":346215409},{"date":"2024-06-28","current":-4.179991,"twenty":-24.930446,"median":-15.76307,"eighty":-7.803407,"marketCap":317328195},{"date":"2024-07-05","current":-4.36173,"twenty":-24.826956,"median":-14.259614,"eighty":-7.683005,"marketCap":331125073},{"date":"2024-07-12","current":-5.457841,"twenty":-24.739524,"median":-13.577524,"eighty":-7.436522,"marketCap":414337494},{"date":"2024-07-15","current":-5.56007,"twenty":-24.730602,"median":-13.28826,"eighty":-7.40699,"marketCap":422098238},{"date":"2024-08-02","current":-4.458278,"twenty":-24.721681,"median":-12.998997,"eighty":-7.379728,"marketCap":338454665},{"date":"2024-08-09","current":-3.873307,"twenty":-24.605701,"median":-11.624103,"eighty":-7.046919,"marketCap":294045964},{"date":"2024-08-16","current":-3.955715,"twenty":-24.550387,"median":-10.892017,"eighty":-5.290869,"marketCap":300302089},{"date":"2024-08-23","current":-4.518382,"twenty":-24.300583,"median":-10.727743,"eighty":-4.552081,"marketCap":343017473},{"date":"2024-08-30","current":-4.558166,"twenty":-24.232778,"median":-10.427767,"eighty":-4.550209,"marketCap":346037753},{"date":"2024-09-06","current":-4.308092,"twenty":-24.091818,"median":-9.970659,"eighty":-4.471909,"marketCap":327053138},{"date":"2024-09-13","current":-3.972766,"twenty":-23.91874,"median":-9.027632,"eighty":-4.36173,"marketCap":301596495},{"date":"2024-09-20","current":-3.932981,"twenty":-23.731387,"median":-8.757535,"eighty":-4.249384,"marketCap":298576215},{"date":"2024-09-27","current":-2.983837,"twenty":-23.401288,"median":-8.2038,"eighty":-4.188739,"marketCap":226520973},{"date":"2024-10-04","current":-2.620093,"twenty":-23.064053,"median":-7.803407,"eighty":-4.107358,"marketCap":198906987},{"date":"2024-10-11","current":-2.585992,"twenty":-21.618758,"median":-7.735255,"eighty":-3.980078,"marketCap":196318176},{"date":"2024-10-18","current":-3.211177,"twenty":-19.474268,"median":-7.570554,"eighty":-3.970492,"marketCap":243779713},{"date":"2024-10-25","current":-2.824699,"twenty":-18.098741,"median":-7.43993,"eighty":-3.926161,"marketCap":214439854},{"date":"2024-10-31","current":-3.023622,"twenty":-17.72781,"median":-7.374617,"eighty":-3.831828,"marketCap":229541252},{"date":"2024-11-08","current":-2.989521,"twenty":-17.672403,"median":-7.116207,"eighty":-3.715421,"marketCap":226952441},{"date":"2024-11-15","current":-1.872701,"twenty":-17.597213,"median":-6.278505,"eighty":-3.207767,"marketCap":207223737},{"date":"2024-11-22","current":-1.556683,"twenty":-17.425798,"median":-5.412407,"eighty":-3.142975,"marketCap":172254731},{"date":"2024-11-29","current":-2.251143,"twenty":-17.188674,"median":-4.774139,"eighty":-3.027032,"marketCap":249100201},{"date":"2024-12-06","current":-1.814179,"twenty":-16.975833,"median":-4.636022,"eighty":-2.984974,"marketCap":200747995},{"date":"2024-12-13","current":-1.740051,"twenty":-16.573007,"median":-4.56385,"eighty":-2.967924,"marketCap":192545389},{"date":"2024-12-20","current":-1.509865,"twenty":-16.354452,"median":-4.538274,"eighty":-2.919045,"marketCap":167074138},{"date":"2024-12-27","current":-1.552781,"twenty":-16.348738,"median":-4.469637,"eighty":-2.836066,"marketCap":171823015},{"date":"2025-01-03","current":-1.529373,"twenty":-16.285886,"median":-4.42582,"eighty":-2.761044,"marketCap":169232719},{"date":"2025-01-10","current":-1.482555,"twenty":-16.158753,"median":-4.36173,"eighty":-2.626913,"marketCap":164052125},{"date":"2025-01-17","current":-1.338201,"twenty":-16.045904,"median":-4.308092,"eighty":-2.550774,"marketCap":148078629},{"date":"2025-01-24","current":-1.322595,"twenty":-15.983052,"median":-4.234207,"eighty":-2.251143,"marketCap":146351764},{"date":"2025-01-31","current":-1.291383,"twenty":-15.904487,"median":-4.202948,"eighty":-1.974139,"marketCap":142898035},{"date":"2025-02-07","current":-1.213354,"twenty":-15.784496,"median":-4.179991,"eighty":-1.846951,"marketCap":134263713},{"date":"2025-02-14","current":-1.186044,"twenty":-15.230253,"median":-4.104819,"eighty":-1.754097,"marketCap":131241700},{"date":"2025-02-21","current":-1.108015,"twenty":-14.458884,"median":-4.025294,"eighty":-1.713911,"marketCap":122607378},{"date":"2025-02-28","current":-1.092409,"twenty":-13.883215,"median":-3.978375,"eighty":-1.612864,"marketCap":120880513},{"date":"2025-03-07","current":-1.01438,"twenty":-13.680373,"median":-3.972766,"eighty":-1.557463,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-13.461819,"median":-3.964176,"eighty":-1.544978,"marketCap":107929030},{"date":"2025-03-21","current":-0.885632,"twenty":-12.929002,"median":-3.924456,"eighty":-1.490358,"marketCap":97999559},{"date":"2025-03-28","current":-0.919716,"twenty":-12.491893,"median":-3.833552,"eighty":-1.429495,"marketCap":101771131},{"date":"2025-04-04","current":-0.667833,"twenty":-11.767663,"median":-3.76816,"eighty":-1.355367,"marketCap":85133388},{"date":"2025-04-11","current":-0.633933,"twenty":-11.317698,"median":-3.708606,"eighty":-1.299966,"marketCap":80811896},{"date":"2025-04-17","current":-0.620373,"twenty":-11.049147,"median":-3.322005,"eighty":-1.283581,"marketCap":79083299},{"date":"2025-04-25","current":-0.72553,"twenty":-10.892017,"median":-3.196968,"eighty":-1.264073,"marketCap":92488388}],"updateTime":1745735004972}}}